Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Northwest Biotherapeutics: Thoughts On Why The Phase 3 Trial Of DCVax-L Is Ongoing
Article By:
SmithOnStocks
Wednesday, September 13, 2017 12:20 PM EDT
The phase 3 trial of DCVax-L in newly diagnosed glioblastoma is continuing even though it has passed the 248 PFS events (mPFS is a primary endpoint) and has probably surpassed 233 OS events (mOS is an independent co-primary endpoint).
In this article: NWBO
Northwest Biotherapeutics, Bristol-Myers Squibb: Success For The Yervoy-Opdivo Combination
Article By:
SmithOnStocks
Thursday, September 7, 2017 10:29 AM EDT
The stoppage at an interim analysis of Bristol-Myers Squibb’s’ Checkmate-214 trial provides meaningful information into assessing the potential for success of Northwest Biotherapeutics.
Northwest Biotehrpeutics: How Does DCVax-L Clinical Data Compare To The CAR-T Therapy Axi-Cel?
Article By:
SmithOnStocks
Friday, August 25, 2017 11:08 AM EDT
It is a paradox that people can look at the Kite phase 2 data on Axi-Cel and pronounce it as stunning as does Biotech Hawk and in the next breath dismiss phase 1/2 data on DCVax-L that appears much more encouraging.
In this article: NWBO
Northwest Biotherapeutics: Why The Phase 3 Trial Of DCVax-L In Newly Diagnosed Glioblastoma Patients Has A Good Chance For Success
Article By:
SmithOnStocks
Friday, July 7, 2017 2:14 PM EDT
This report is an extensive update on almost everything I know about the DCVax-L phase 3 trial and is over 20 pages long. The catalyst for this report was the recent information on the still blinded phase 3 trial presented in June at ASCO.
In this article: NWBO
Northwest Biotherapeutics: Why The Phase 3 Trial Of DCVax-L In Newly Diagnosed Glioblastoma Patients Has A Good Chance For Success
I'm bullish on $NWBO. Please let us know if your outlook changes at all.